Department of Economics and Business Economics

The Effect of Adjunctive Mangosteen Pericarp on Cognition in People With Schizophrenia: Secondary Analysis of a Randomized Controlled Trial

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Wolfgang Marx, BL Deakin Business School, Deakin University
  • ,
  • David R Skvarc, BL Deakin Business School, Deakin University
  • ,
  • Mohammadreza Mohebbi, BL Deakin Business School, Deakin University
  • ,
  • Adam J Walker, BL Deakin Business School, Deakin University
  • ,
  • Alcy Meehan, BL Deakin Business School, Deakin University
  • ,
  • Alyna Turner, BL Deakin Business School, Deakin University, The University of Newcastle
  • ,
  • Andrea Baker, The Park Center for Mental Health
  • ,
  • Seetal Dodd, BL Deakin Business School, Deakin University, University of Melbourne
  • ,
  • Sue M Cotton, Orygen, University of Melbourne
  • ,
  • James Graham Scott, The Park Center for Mental Health, QIMR Berghofer Medical Research Institute Mental Health Programme, Metro North Mental Health Service Herston
  • ,
  • Bianca E Kavanagh, BL Deakin Business School, Deakin University
  • ,
  • Melanie M Ashton, BL Deakin Business School, Deakin University
  • ,
  • Ellie Brown, University of Melbourne, Orygen
  • ,
  • John J McGrath
  • Michael Berk, BL Deakin Business School, Deakin University
  • ,
  • Olivia May Dean, BL Deakin Business School, Deakin University, University of Melbourne

Background: Cognitive impairment is prevalent and often highly burdensome in people with schizophrenia. The aim of this study was to investigate if mangosteen (Garcinia mangostana Linn.) pericarp extract may be an effective intervention to improve cognitive performance in this population. Methods: This was a secondary analysis of a larger randomized placebo-controlled trial that investigated a 24-weeks intervention of mangosteen pericarp extract supplementation in people diagnosed with schizophrenia. A subset of n = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: psychomotor function, attention, visual learning and memory (visual and working). Subgroup analyses investigated whether baseline clinical parameters (baseline cognitive functioning, illness severity and duration, depressive symptoms) moderated the relationship between mangosteen pericarp extract intervention and change in cognitive outcomes. Results: There were no significant between-group changes in any cognitive outcomes assessed. Subgroup analysis based on baseline cognition and clinical characteristics did not reveal any significant between-group difference in change. Conclusions: Mangosteen pericarp extract did not affect cognitive outcomes in people with schizophrenia. Further investigation regarding optimal dosing strategies for mangosteen interventions and the testing of additional cognitive domains may be warranted. Trial Registration: ANZCTR.org.au identifier: ACTRN12616000859482, registered 30 June 3 2016.

Original languageEnglish
Article number626486
JournalFrontiers in Psychiatry
Volume12
Pages (from-to)626486
ISSN1664-0640
DOIs
Publication statusPublished - Jun 2021

Bibliographical note

Copyright © 2021 Marx, Skvarc, Mohebbi, Walker, Meehan, Turner, Baker, Dodd, Cotton, Scott, Kavanagh, Ashton, Brown, McGrath, Berk and Dean.

See relations at Aarhus University Citationformats

ID: 219294289